Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study

详细信息    查看全文

• 作者：Mehmet Ali Erkurt^a ; ^{erkurtali@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Ilhami Berber^a ; Emre Tekgü ; ndü ; z^b ; Mehmet Hilmi Dogu^c ; Serdal Korkmaz^d ; Cengiz Demir^e ; Mehmet Yilmaz^f ; Olga Meltem Akay^g ; Ciğdem Pala^h ; Yusuf Bilenⁱ ; Emin Kaya^a ; Ismail Sari^c ; Mehmet Sencan^j ; Irfan Kuku^a ; Fevzi Altuntaş^b ; ^k ; Mehmet Sinan Dal^b ; Ismet Aydogdu^l
• 关键词：Autologous stem cell transplantation ; CNS lymphoma ; PCNSL ; Methotrexate ; High-dose chemotherapy
• 刊名：Transfusion and Apheresis Science
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：54
• 期：1
• 页码：80-84
• 全文大小：435 K

文摘

We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1–71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal.